Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma

J Am Acad Dermatol. 2013 Jul;69(1):e28-9. doi: 10.1016/j.jaad.2013.01.012.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects*
  • Indoles / therapeutic use
  • Melanoma / drug therapy*
  • Melanoma / secondary*
  • Middle Aged
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology*
  • Skin Pigmentation / drug effects
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects*
  • Sulfonamides / therapeutic use
  • Vemurafenib
  • Vitiligo / chemically induced*

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib